Latest News - Psivida

Tuesday, July 11, 2017 | Alimera Sciences, Psivida

Alimera Sciences To Expand Iluvien Indication in Europe for Posterior Uveitis

Alimera Sciences announced that it secured the rights to pursue posterior uveitis, a secondary indication for Iluvien, in the European Union (EU), the Middle East and Africa.  Alimera secured …

Read the full story

Monday, July 10, 2017 | Retina, Psivida

pSivida Out-Licenses EMEA Rights for Durasert Treatment for Posterior Segment Uveitis While Retaining US Commercial Rights

pSivida announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences that grants Alimera rights to pSivida’s Durasert 3-year treatment for posterior segment …

Read the full story

Thursday, June 22, 2017 | Retina, Psivida

pSivida Submits Marketing Authorization Application for Approval of Durasert 3-Year Treatment for Posterior Segment Uveitis in the EU

pSivida Corp. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market the company’s Durasert 3-year treatment for posterior s…

Read the full story

Tuesday, June 13, 2017 | Clinical Trials, Psivida

pSivida’s Durasert 3-year Treatment for Posterior Segment Uveitis Achieves Primary Efficacy Endpoint

A second phase 3 trial of pSivida's Durasert 3-year treatment for posterior segment uveitis achieved the trial’s primary endpoint. The study involved 153 patients and the primary endpoint wa…

Read the full story

Wednesday, November 09, 2016 | Management/Leadership, Psivida

Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development

pSivida Corp. announced that Deb Jorn has joined the company as Executive Vice President of Corporate and Commercial Development, a newly created position reporting directly to Nancy Lurker, pSivida&r…

Read the full story

Tuesday, December 22, 2015 | Clinical Trials, Psivida

pSivida's Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial of Posterior Uveitis Treatment

pSivida announced positive topline results from its first phase 3 clinical trial evaluating the safety and efficacy of Medidur for the treatment of chronic noninfectious uveitis affecting the posterio…

Read the full story

Monday, September 28, 2015 | Clinical Trials, Psivida

pSivida Announces NDA for Medidur, Now Planned Using 6-Month Efficacy Data from Both Phase 3 Trials

A new drug application (NDA) was filed for Medidur for posterior uveitis based on 6-month efficacy data for both phase 3 trials, according to a pSivida news release. The FDA has advised pSivida that t…

Read the full story

Monday, July 13, 2015 | Clinical Trials, Psivida

pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase 2 Study of Medidur for Uveitis

pSivida announced positive top line results from a phase 2 investigator-sponsored study of Medidur for uveitis affecting the posterior of the eye (posterior, intermediate and pan-uveitis), according t…

Read the full story

Wednesday, July 08, 2015 | Clinical Trials, Psivida

pSivida Announces Top-Line Results from Investigator-Sponsored Phase 2 Study of Medidur for Uveitis to Be Reported Next Week

pSivida announced that top line results from an investigator-sponsored, phase 2 study of pSivida’s Medidur for uveitis will be presented at the 33rd Annual Scientific Meeting of the American Soc…

Read the full story

Tuesday, May 12, 2015 | Pharmaceutical, Psivida

pSivida Announces Two Tech Evaluation Agreements with Global Pharmaceutical Company

pSivida Corp announced that it has signed two funded technology evaluation agreements with a global pharmaceutical company. The agreements will each evaluate the use of pSivida’s Durasert techno…

Read the full story

Tuesday, April 14, 2015 | Product Releases, Psivida

pSivida Reports Iluvien for DME Approved in Poland

pSivida Corp. announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted marketing authorization to Iluvien for the treatment of visi…

Read the full story

Thursday, March 26, 2015 | Clinical Trials, Psivida

pSivida Completes Targeted Enrollment of Phase 3 Trial of Medidur for Posterior Uveitis

pSivida announced the completion of the originally targeted enrollment of 120 patients in its pivotal phase 3 clinical trial of Medidur for the treatment of posterior uveitis, according to a company n…

Read the full story

Tuesday, February 17, 2015 | Product Releases, Psivida

pSivida Announces US Shipments of Iluvien for DME to Start February 23

pSivida Corp. announced that initial nationwide shipments of Iluvien for diabetic macular edema (DME) are scheduled to begin in the United States on February 23, according to a company news release. …

Read the full story

Tuesday, January 27, 2015 | Retina, Psivida

pSivida Reports Iluvien Receives Marketing Authorization in Two More EU Countries

pSivida Corp. announced that Finland and Luxembourg have granted marketing authorization to Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) consider…

Read the full story